{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"17"}],"units":"Participants"}],"description":"A DLT is defined as an adverse event that is likely related to the study medication or combination, and fulfils any one of the following criteria, graded according to the NCI-CTCAE (National Cancer Institute-Common Terminology Criteria for Adverse Events) version 5.0:\n\n* Grade 3 thrombocytopenia associated with clinically significant bleeding and requiring platelet transfusion or Grade 4 thrombocytopenia of any duration.\n* Grade ≥3 febrile neutropenia\n* Grade ≥3 anemia requiring a blood transfusion\n* Other Grade ≥4 toxicities, excluding few nonhematologic Toxicities\n* Any other significant toxicity deemed by the investigatory to be dose-limiting, such as: any toxicity that is possibly related to the study medication that requires the withdrawal of the participant from the study during 28-day DLT observation period), persistent Grade \\>2 toxicities causing a delay of LY3475070 study treatment \\>14 days during the 28-day DLT observation period.","groups":[{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG000","title":"Cohort A - 150mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG001","title":"Cohort A - 300mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG002","title":"Cohort A - 300mg BID LY3475070"},{"description":"Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG003","title":"Cohort A - 600mg QD LY3475070"},{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG004","title":"Cohort B - 150mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG005","title":"Cohort B - 150mg BID LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG006","title":"Cohort B - 300mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study","id":"OG007","title":"Cohort B - 300mg BID LY3475070 + Pembrolizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants enrolled in the phase 1a who either completed 28 days of follow-up and at least 75% of LY3475070 treatment doses or discontinued treatment prior to 28 days due to a DLT.","reportingStatus":"POSTED","timeFrame":"Up to 28 days from the first dose","title":"Number of Participants With Dose Limiting Toxicities (DLTs)","type":"PRIMARY","unitOfMeasure":"Participants"}